A 61-year-old woman with a systemic history of obesity, arterial hypertension, renal failure with good control at present and type 2 diabetes mellitus of 7 years of evolution on insulin treatment for 2 years and in the last 3 months rosiglitiazone 4mg per day (Avandia®, Glaxosmithkline) was associated with good glycaemic control. The patient's ophthalmological history included diffuse bilateral macular oedema treated with laser six months earlier, with maximum vision of 0.3 in the right eye and 0.250 in the left eye. He came to the ophthalmology department reporting severe loss of vision that had prevented him from carrying out his daily work for the last two months. The systemic examination revealed a weight gain of 7 kilos (reported by her primary care physician) with peripheral oedema in the extremities. Visual acuity was 0.05 in both eyes. Bilateral diffuse severe diffuse macular oedema is seen in the fundus. Due to generalised fluid retention, a systemic examination was performed, ruling out renal and/or cardiac pathology and establishing the association with rosiglitazone. Rosiglitazone was withdrawn and after two months the patient had lost 5kg and the leg oedema had disappeared. Macular oedema did not decrease and visual acuity at three months remained at 0.05 in both eyes.

